They formulated that carrying EGFR mutations was obviously associated with the absence of ILD in patients with lung adenocarcinoma (OR: 17.41, 95% CI: 3.54–315.34, p < 0.001), independent of gender and smoking status. Here, EGFR is linked to interstitial lung disease.